Pharmacy

PhD Opportunities with Prof Thakur Raghu Raj Singh

Queen's University Belfast

School of Pharmacy

Location
Belfast, United Kingdom
Funding
See university guidance
Application deadline
See university guidance

About the project

Professor Raj Thakur, PhD, is an internationally recognised expert in drug delivery and pharmaceutics, with over 20+ years of R&D experience. He holds a PhD in Drug Delivery, an MSc in Pharmaceutical Sciences, and a Bachelor’s degree in Pharmacy. He currently serves as Chair in Pharmaceutics at the School of Pharmacy, Queen’s University Belfast, UK.

His research focuses on the design and development of innovative long-acting drug delivery systems, with a particular interest in reducing the burden of frequent intravitreal injections for chronic retinal diseases such as age-related macular degeneration and diabetic macular edema. He leads The GODDs Lab (Great Ocular Drug Delivery Science Lab), one of the foremost ocular drug delivery research groups globally, and has supervised over 20+ PhD students and 25+ postdoctoral researchers.

Professor Raj Thakur has been Principal Investigator on projects worth several millions in funding, supported by UKRI, the EU, Invest Northern Ireland, venture capital, and pharmaceutical industry partners. He has authored over 200+ peer-reviewed publications, five books, and holds seven patents on sustained-release and implantable delivery platforms. He serves on the Editorial Board of Ophthalmic Drug Delivery and Frontiers in Drug Delivery and is an Associate Editor for Drug Delivery and Translational Research (DDTR). He is a regular invited speaker at national and international conferences.

In addition to his academic leadership, Professor Thakur is the Founder and Chief Technology Officer of Re-Vana Therapeutics , a Queen’s University spinout company pioneering long-acting ocular drug delivery technologies. Under his scientific leadership, Re-Vana has raised significant Seed, pre-Series A and Series A funding and recently entered a landmark strategic collaboration with Boehringer Ingelheim valued at over $1 billion in potential milestones , to co-develop sustained-release therapies targeting chronic retinal diseases.

Professor Thakur remains passionate about translational research and innovation that directly impact patient care and welcomes collaboration and PhD applicants interested in advancing next-generation drug delivery systems.

  • Prof Thakur Raghu Raj Singh: Chair of Pharmaceutics | Founder, Re-Vana Therapeutics School of Pharmacy, Queen’s University Belfast

Contact info

  • View Academic Profile
  • askmhls@qub.ac.uk
  • +44 (0)28 9097 5814, +44 (0)28 9097 2719
  • @rthakur01 and ThakurLabQUB

Research Interests

Professor Thakur welcomes PhD applications in the broad area of drug delivery, with a focus on the following research themes:

Make a PhD enquiry

  • Controlled drug delivery systems for the treatment of chronic disorders
  • Delivery of small molecules and biologics using advanced platforms such as injectable implants, preformed implants, microparticles, and nanoparticles for ocular applications
  • Synthesis and characterisation of block copolymers for sustained and targeted drug delivery
  • Electrospun drug delivery systems for enhanced topical ocular delivery
  • Thermoresponsive and in situ depot-forming hydrogel systems for long-acting formulations
  • Nanoparticle-based platforms offering improved drug loading and enhanced penetration across biological barriers
  • Microneedle technologies for minimally invasive transscleral and transcorneal delivery
  • Medical device development for drug delivery applications

Public outreach & key achievements

Professor Thakur’s pioneering research in ocular drug delivery has translated into high-impact public engagement and entrepreneurial success. His work led to the founding of Re-Vana Therapeutics Ltd , a Queen’s University Belfast spinout developing long-acting drug delivery technologies to address unmet needs in chronic retinal diseases.

Re-Vana has grown into a thriving biotech company with over 20 full-time employees , raising multi-million-pound investment across Seed, Pre-Series A, and Series A rounds from leading venture capital firms in the USA, EU, and UK . The company’s platform technologies aim to reduce the frequency of intravitreal injections and improve therapeutic outcomes for diseases such as wet age-related macular degeneration and diabetic macular edema.

Notable public and entrepreneurial achievements include:

Through these achievements, Professor Thakur exemplifies how academic research can deliver global impact through entrepreneurship, job creation, and patient-centred innovation. He remains committed to inspiring young scientists and contributing to the innovation ecosystem across the UK and beyond.

  • Featured in The DNA of Innovation, Volume V: New Voices, New Impact , recognising leading research with transformative societal and commercial impact.
  • Winner, ‘Life and Health’ category, INVENT 2015 , awarded by NISP CONNECT at the Northern Ireland Science Park.
  • Silver Award Winner, MassChallenge UK 2015 , one of the top global startup accelerators (selected from over 2,200 international applicants).
  • Winner, Retina Innovation Award for Drug Delivery 2022 at the OIS Retina Summit , a major recognition within the global ophthalmology industry.
  • Winner, Business Innovation Award 2022 , sponsored by Belfast City Council , recognising commercial innovation and regional economic impact.
  • In 2025, Re-Vana entered a landmark strategic collaboration with Boehringer Ingelheim , a deal valued at over $1 billion in potential development and commercial milestones , positioning the company at the forefront of next-generation retinal therapeutics.

Research students

PhD Title | Depot forming nanoparticles for sustained ocular drug delivery

Name | Yu Wu

Country | China

Year of Study | 2018-2021

PhD Title | Electrospinning-based ocular inserts for enhanced topical delivery

Name | Shubhamkumar M Baviskar

Country | India

Year of Study | 2018-2021

EdD Title | Synthesis and characterization of block polymers micelles

Name | Ahmad Assiri

Country | Saudi

Year of Study | 2019-2022

Alumni: Where are they now

PhD Title | Sustained release biodegradable ocular drug delivery systems

Name | Dr Hannah McMillan

Year of Study | 2012-2015

Country | UK

Current Position | Formulation Scientist at Actavis, Belfast

PhD Title | Development and Evaluation of Biodegradable Implants for long-term ocular drug delivery

Name | Dr Kathryn McAvoy

Year of Study | 2014-2017

Country | Northern Ireland

Current Position | Formulation Scientist Warner Chilcott

Discover More

  • Faculty of Medicine, Health & Life Sciences
  • School of Pharmacy
  • Materials and Advanced Technologies for Healthcare

Research areas

Pharmacydrug delivery

Related PhD opportunities

PhD Pharmacy

A statin-releasing vaginal ring for treating bacterial vaginosis

Queen's University Belfast

"This project aims to develop and evaluate a novel statin-releasing vaginal ring as a long-acting treatment and prevention strategy for…

Location
Belfast, United Kingdom
Deadline
See university guidance
Funding
External funding